11 Jan 2019 Research

Lymphoma: Understanding relapse and treatment resistance

What is this research looking at?

Our immune system is remarkable. It is made up of many different types of immune cells that work together to protect the body from infection by pathogens such as bacteria, viruses and parasites.

We are investigating what happens when a certain type of cell in the immune system, known as B cells, starts growing out of control and develops into blood cancers such as leukaemia, lymphoma and myeloma.

We want to know what happens when B cells mature normally from precursor cells in the bone marrow and discover what has gone wrong when they turn into cancer cells instead.

Considerable success has been achieved in the treatment of lymphoma. However, a significant unmet need remains: roughly 40% of patients either do not respond to treatment or the condition recurs after treatment. Currently, our ability to predict which patients will fail treatment is poor.

By taking a detailed look at B cells as they develop and specialise, we can spot small groups of dangerous cells that are particularly likely to turn into cancer and identify the genetic faults that drive B cells to grow out of control.

We are using our knowledge to create new models for the development of B cells and blood cancers in the lab, so we can find new ways to treat or even prevent these deadly diseases.

Our research uses a model of lymphoma to test the response to treatments and development of resistance. A main advantage of the model is that we can interrogate these questions on a well-defined scenario and can perform iterative tests and predictions. Further, the model generated in this project will allow initial testing of novel treatments.

What could this mean for people with leukaemia?

This research could inform the medical decision of when to use combination and novel therapies for patients with a higher probability of developing resistance to standard treatment, alongside bringing safer treatments to patients.

Official project title: Development of a model system to study diffuse large B cell lymphoma clonal evolution

Related posts

Angela Smith-Morgan to step down from her role as Co CEO of Leukaemia UK

25 August 2020

Angela Smith-Morgan to step down from her role as Co CEO of Leukaemia UK

After eight successful years with us, Angela Smith-Morgan will be stepping down from her role as Co CEO of Leukaemia UK on 3rd September.

Leukaemia charities unite in Blood Cancer Awareness Month to improve diagnosis and the chances of survival

20 September 2021

Leukaemia charities unite in Blood Cancer Awareness Month to improve diagnosis and the chances of survival

Leading UK leukaemia charities Leukaemia Care and Leukaemia UK have announced a new collaboration to increase awareness of the signs and symptoms of leukaemia and drive improvements in the diagnosis of the disease. The campaign, Spot Leukaemia, is running throughout September – Blood Cancer Awareness Month.

One Cancer Voice writes to Sajid Javid ahead of 10-Year Cancer Plan

1 August 2022

One Cancer Voice writes to Sajid Javid ahead of 10-Year Cancer Plan

Today, with over 50 cancer charities, we wrote to the Secretary of State for Health & Social Care, Sajid Javid, to set out our expectation for next month’s 10-Year Cancer Plan….

£200 grants for people affected by leukaemia once again available

4 April 2023

£200 grants for people affected by leukaemia once again available

Leukaemia UK and Leukaemia Care have this month relaunched the ‘Cost of Living Fund’, providing financial grants of £200 to patients with leukaemia, myelodysplastic syndrome (MDS) or myeloproliferative neoplasms (MPNs),…